Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Phentermine And Topiramate

Stage Phase 3Stale

Sponsor VIVUS LLC

Route oral and injection

Class Sympathomimetic combo

Mechanism 3.75 mg phentermine/23 mg topiramate

Sources

registry, as of 2012-09-10Stale

https://clinicaltrials.gov/study/NCT00554216

Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults. Overall status COMPLETED. Phases PHASE3. Lead sponsor VIVUS LLC. Enrollment 1267. Conditions Obesity. The purpose of this study is to evaluate the efficacy and safety of two doses of VI-0521 compared to placebo in treatment of obesity in an adult population with BMI ≥ 35. Percentage of Subjects With at Least 5% Weight Loss at Week 56 Placebo 17.3 Percentage of Subjects With at Least 5% Weight Loss at Week 56 VI-0521 Low 44.9 Percentage of Subjects With at Least 5% Weight Loss at Week 56 VI-0521 Top 66.7 nausea Placebo 24 diarrhea Placebo 23 nausea VI-0521 Low 14 diarrhea VI-0521 Low 12 nausea VI-0521 Top 37 diarrhea VI-0521 Top 24

ClinicalTrials.gov NCT00554216 protocol and results modules

registry, as of 2015-03-30Stale

https://clinicaltrials.gov/study/NCT00563368

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults. Overall status COMPLETED. Phases PHASE3. Lead sponsor VIVUS LLC. Enrollment 756. Conditions Obesity. The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have effica Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF Placebo 15.5 Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF PHEN 7.5 mg 43.3 Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF TPM 46 mg 39.2 Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF VI-0521 Mid 62.1 Percentage of Subjects With at Leas

ClinicalTrials.gov NCT00563368 protocol and results modules

registry, as of 2026-05-05Stale

https://clinicaltrials.gov/study/NCT04007393

SMART Use of Medication for the Treatment of Adolescent Severe Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor University of Minnesota. Enrollment 150. Conditions Adolescent Obesity. This study will examine the timing and sequence of using adjunct obesity pharmacotherapy for adolescents with severe obesity who do not respond to lifestyle modification therapy alone. deaths Arm 1: LSMT 12 +Phentermine 0 nausea Arm 1: LSMT 12 +Phentermine 0 deaths Arm 1: LSMT +12+Phentermine+Topiramate 0 nausea Arm 1: LSMT +12+Phentermine+Topiramate 2 deaths Arm 1: LSMT 12+Phentermine+Placebo 0 nausea Arm 1: LSMT 12+Phentermine+Placebo 2 deaths Arm 2: LSMT 24+Phentermine 0 nausea Arm 2: LSMT 24+Phentermine 1 deaths Arm 2: LSMT 24X Phentermine+Topiramate 0 nausea Arm 2: LSMT 24X Phentermine+Topiramate 2 deaths Arm 2: LSMT 24+Phentermine+Placebo 0 nausea Arm 2: LSMT 24+Phentermine+Placebo 1

ClinicalTrials.gov NCT04007393 protocol and results modules

registry, as of 2026-11-06

https://clinicaltrials.gov/study/NCT07790913

Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor St. Jude Children's Research Hospital. Enrollment 100. Conditions Acute Lymphoblastic Leukemia in Remission; Hodgkin Lymphoma in Remission; Non-Hodgkin Lymphoma in Remission; Cancer Survivorship. This study is evaluating whether a weight-loss medication (PHEN/TOP) combined with healthy lifestyle counseling is safe, well tolerated, and can help reduce obesity in adolescents and young adults who are in remission from ALL, Hodgkin lymphoma, or non-Hodgkin lymphoma. Participa

ClinicalTrials.gov NCT07790913 protocol and results modules

registry, as of 2026-05-26Stale

https://clinicaltrials.gov/study/NCT04298203

Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor University of Minnesota. Enrollment 100. Conditions Obesity. Long-term weight loss maintenance is seldom achieved by individuals with obesity owing to numerous biological adaptations occurring in the post-weight loss setting, including neuroendocrine-mediated changes in appetite/satiety and reduction of energy expenditure. Following weight

ClinicalTrials.gov NCT04298203 protocol and results modules

registry, as of 2023-05-16Stale

https://clinicaltrials.gov/study/NCT04721873

Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients. Overall status RECRUITING. Phases PHASE2. Lead sponsor University of California, San Diego. Enrollment 40. Conditions Colitis, Ulcerative; Obesity. Approximately 20-40% of patients with ulcerative colitis (UC) are obese. The investigators have demonstrated that obesity adversely impacts disease course in patients with UC, leading to higher risk of persistently active disease, surgery, hospitalization, and treatment failure,

ClinicalTrials.gov NCT04721873 protocol and results modules

registry, as of 2019-09-04Stale

https://clinicaltrials.gov/study/NCT02301416

Qsymia as an Adjunct to Surgical Therapy in the Superobese. Overall status COMPLETED. Phases PHASE2. Lead sponsor Wake Forest University Health Sciences. Enrollment 25. Conditions Obesity; Metabolic Surgery; Weight Loss; Bariatric Surgery Procedures. This study tests the efficacy of the medication, Qsymia, as an adjunct therapy in superobese individuals planning to undergo weight loss surgery. Individuals taking the medication before and after surgery will be compared to historical controls who had surgery without taking the deaths Phentermine/Topiramate 0

ClinicalTrials.gov NCT02301416 protocol and results modules

registry, as of 2026-10-16Stale

https://clinicaltrials.gov/study/NCT06299891

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Seattle Children's Hospital. Enrollment 24. Conditions Hypothalamic Obesity; Hypothalamic Tumor; Craniopharyngioma. Hypothalamic obesity (HO) refers to the substantial weight gain that often complicates hypothalamic brain tumors. Children with this treatment-recalcitrant form of obesity have excess rates of metabolic sequelae compared to otherwise healthy children with similar obesity, and lat

ClinicalTrials.gov NCT06299891 protocol and results modules

registry, as of 2026-06-15Stale

https://clinicaltrials.gov/study/NCT04621929

Phentermine/Topiramate for Uric Acid Stones. Overall status COMPLETED. Phases PHASE2. Lead sponsor University of Florida. Enrollment 19. Conditions Obesity; Uric Acid Stones; Type 2 Diabetes Mellitus in Obese; Pre-Diabetes. The investigator proposes an 18 month, feasibility pilot study, randomizing obese and diabetic individuals with pure uric acid nephrolithiasis (UAN) or mixed calcium oxalate (CO) UAN to either phentermine/topiramate or a pragmatic control group who will remain on their standard m deaths Allocated to Intervention/Treatment 0 deaths Allocated to Pragmatic Control 0

ClinicalTrials.gov NCT04621929 protocol and results modules

registry, as of 2025-05-23Stale

https://clinicaltrials.gov/study/NCT04095104

Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds. Overall status COMPLETED. Phases PHASE2. Lead sponsor University of Colorado, Denver. Enrollment 13. Conditions Obesity, Morbid; Bariatric Surgery; Adolescent; Young Adult; Drug Therapy. The goal of this pilot study is to establish the feasibility and initial efficacy of the combination of phentermine and topiramate for adolescents and young adults who require additional risk reduction after bariatric surgery. This study will use a randomized, placebo-controlled, Change in Hemoglobin A1c (HbA1c) (%) Phentermine & Topiramate 0.05 Percentage of glycated hemoglobin Change in Hemoglobin A1c (HbA1c) (%) Placebo 0.1 Percentage of glycated hemoglobin deaths Phentermine & Topiramate 0 diarrhea Phentermine & Topiramate 1 deaths Placebo 0 diarrhea Placebo 3

ClinicalTrials.gov NCT04095104 protocol and results modules

registry, as of 2025-05-31Stale

https://clinicaltrials.gov/study/NCT04572217

Medications After Adolescent Bariatric Surgery. Overall status WITHDRAWN. Phases PHASE2. Lead sponsor Janey Pratt. Enrollment 0. Conditions Pediatric Obesity. This study will assess the feasibility to assess practicality of early weight loss medication usage in adolescent patients post-VSG with inadequate weight loss. Participants who enroll in the study will be prescribed off-label use of weight loss medications for a period of up to

ClinicalTrials.gov NCT04572217 protocol and results modules

registry, as of 2026-01-14Stale

https://clinicaltrials.gov/study/NCT05579249

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America. Overall status COMPLETED. Phases PHASE4. Lead sponsor Novo Nordisk A/S. Enrollment 500. Conditions Obesity. The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functi Percentage Change in Body Weight Semaglutide 2.4 mg -13.6 Percentange change in body weight Baseline (week 0), end of treatment (week 52) Percentage Change in Body Weight Other Anti-obesity Medications (AOMs) -7.4 Percentange change in body weight Baseline (week 0), end of treatment (week 52) deaths Semaglutide 2.4 mg 0 deaths Other Anti-obesity Medications (AOMs) 2

ClinicalTrials.gov NCT05579249 protocol and results modules

Studies

Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

Registry NCT00554216

Phase Phase 3

Status Completed

Enrollment 1267

VI-0521 Low

Weeks 56

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 44.9 %, week 56Stale

participants with nausea, 14 participantsStale

participants with diarrhea, 12 participantsStale

VI-0521 Top

Weeks 56

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 66.7 %, week 56Stale

participants with nausea, 37 participantsStale

participants with diarrhea, 24 participantsStale

Placebo

Weeks 56

Population Obesity

participants with at least 5 percent body weight loss, 17.3 %, week 56Stale

participants with nausea, 24 participantsStale

participants with diarrhea, 23 participantsStale

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

Registry NCT00563368

Phase Phase 3

Status Completed

Enrollment 756

VI-0521 Top

Regimen once daily

Weeks 28

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 66 %, week 28Stale

participants with nausea, 8 participantsStale

participants with diarrhea, 6 participantsStale

VI-0521 Mid

Regimen once daily

Weeks 28

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 62.1 %, week 28Stale

participants with nausea, 9 participantsStale

participants with diarrhea, 4 participantsStale

TPM 46

Regimen once daily

Weeks 28

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 39.2 %, week 28Stale

participants with nausea, 8 participantsStale

participants with diarrhea, 3 participantsStale

TPM 92

Regimen once daily

Weeks 28

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 48.6 %, week 28Stale

participants with nausea, 5 participantsStale

participants with diarrhea, 6 participantsStale

PHEN 7.5

Regimen once daily

Weeks 28

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 43.3 %, week 28Stale

participants with nausea, 5 participantsStale

participants with diarrhea, 1 participantsStale

PHEN 15

Regimen once daily

Weeks 28

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 46.2 %, week 28Stale

participants with nausea, 6 participantsStale

participants with diarrhea, 4 participantsStale

Placebo

Regimen once daily

Weeks 28

Population Obesity

participants with at least 5 percent body weight loss, 15.5 %, week 28Stale

participants with nausea, 5 participantsStale

participants with diarrhea, 5 participantsStale

SMART

Registry NCT04007393

Phase Phase 2

Status Completed

Enrollment 150

Start 2019-11-21

Primary completion 2025-03-11

Study completion 2025-03-11

Catalyst Primary completion. 2025-03-11. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

LSMT 12

Population Adolescent Obesity

deaths

participants with nausea, 0 participantsStale

LSMT 24

Population Adolescent Obesity

deaths

participants with nausea, 1 participantsStale

Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma

Registry NCT07790913

Phase Phase 2

Status Not yet recruiting

Enrollment 100

phentermine topiramate extended release (PHEN/TOP) + Health Behavior and Lifestyle Counseling

Regimen every 4 weeks

Weeks 24

Population Acute Lymphoblastic Leukemia in Remission; Hodgkin Lymphoma in Remission; Non-Hodgkin Lymphoma in Remission; Cancer Survivorship

Health Behavior and Lifestyle Counseling Alone (SOC [Standard of Care])

Regimen every 4 weeks

Weeks 24

Population Acute Lymphoblastic Leukemia in Remission; Hodgkin Lymphoma in Remission; Non-Hodgkin Lymphoma in Remission; Cancer Survivorship

Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity

Registry NCT04298203

Phase Phase 2

Status Completed

Enrollment 100

Start 2021-08-04

Primary completion 2026-05-22

Study completion 2026-05-22

Catalyst Primary completion. 2026-05-22. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Meal Replacement Therapy

Regimen once daily

Comparator placebo

Population Obesity

Phentermine/Topiramate

Regimen once daily

Comparator placebo

Population Obesity

Placebo

Regimen once daily

Population Obesity

Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

Registry NCT04721873

Phase Phase 2

Status Recruiting

Enrollment 40

Start 2020-12-18

Primary completion 2024-06-30

Study completion 2024-06-30

Intervention

Regimen once daily

Weeks 22

Comparator placebo

Population Colitis, Ulcerative; Obesity

Placebo

Regimen once daily

Weeks 22

Population Colitis, Ulcerative; Obesity

Qsymia as an Adjunct to Surgical Therapy in the Superobese

Registry NCT02301416

Phase Phase 2

Status Completed

Enrollment 25

Primary completion 2018-06-27

Study completion 2018-06-27

Phentermine/topiramate

Population Obesity; Metabolic Surgery; Weight Loss; Bariatric Surgery Procedures

deaths

Historical Control

Population Obesity; Metabolic Surgery; Weight Loss; Bariatric Surgery Procedures

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

Registry NCT06299891

Phase Phase 2

Status Active, not recruiting

Enrollment 24

Start 2025-03-01

Primary completion 2026-10-31

Study completion 2026-11-30

Catalyst Primary completion. 2026-10-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Drug Intervention

Comparator placebo

Population Hypothalamic Obesity; Hypothalamic Tumor; Craniopharyngioma

Placebo

Population Hypothalamic Obesity; Hypothalamic Tumor; Craniopharyngioma

Phentermine/Topiramate for Uric Acid Stones

Registry NCT04621929

Phase Phase 2

Status Completed

Enrollment 19

Start 2021-03-31

Primary completion 2024-11-14

Study completion 2024-11-14

Allocated to intervention/treatment

Regimen daily

Population Obesity; Uric Acid Stones; Type 2 Diabetes Mellitus in Obese; Pre-Diabetes

deaths

Allocated to pragmatic control

Regimen daily

Population Obesity; Uric Acid Stones; Type 2 Diabetes Mellitus in Obese; Pre-Diabetes

deaths

Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds

Registry NCT04095104

Phase Phase 2

Status Completed

Enrollment 13

Start 2020-01-15

Primary completion 2022-01-25

Study completion 2022-01-25

Phentermine & Topiramate

Weeks 12

Comparator placebo

Population Obesity, Morbid; Bariatric Surgery; Adolescent; Young Adult; Drug Therapy

change in HbA1c, 0.05 Percentage of glycated hemoglobin, week 12Stale

deaths

participants with diarrhea, 1 participantsStale

Placebo Drugs

Weeks 12

Population Obesity, Morbid; Bariatric Surgery; Adolescent; Young Adult; Drug Therapy

change in HbA1c, 0.1 Percentage of glycated hemoglobin, week 12Stale

deaths

participants with diarrhea, 3 participantsStale

MAABS Protocol

Registry NCT04572217

Phase Phase 2

Status Withdrawn

Enrollment 0

Start 2022-06-01

Primary completion 2022-06-01

Study completion 2022-06-01

Medication Group

Regimen daily

Weeks 12

Population Pediatric Obesity

Non-Medication Group

Regimen daily

Weeks 12

Population Pediatric Obesity

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Registry NCT05579249

Phase Phase 4

Status Completed

Enrollment 500

Start 2023-01-19

Primary completion 2024-11-27

Study completion 2024-11-27

Semaglutide

Regimen once weekly

Weeks 52

Population Obesity

percent change in body weight, -13.6 %Stale

deaths

Other anti-obesity medication

Regimen once weekly

Weeks 52

Population Obesity

percent change in body weight, -7.4 %Stale

deaths